Pipeline Trends is produced by UMass Medical School’s Clinical Pharmacy Services division and is distributed at least once a year. This edition provides a comprehensive overview of:
- Promising New Agents: Abaloparatide, Cannabidiol, Dupilumab, and others
- Projected Generic Entry: Strattera®, Tamiflu®, Truvada®, Zetia®, and others
- Investigational Indications: Cabozantinib and Tofacitinib
- FDA Updates
- Industry Trends